Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2012-07-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1209292109PMID 22753489PMCID PMC3406843
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

  2012cited by this paper
• Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

  2011cited by this paper
• Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.

  2011cited by this paper
• Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

  2011cited by this paper
• Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

  2010cited by this paper
• Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

  2009cited by this paper
• A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

  2009cited by this paper
• An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

  2008cited by this paper
• Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

  2007cited by this paper
• Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients1

  2006cited by this paper
• HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity

  2005cited by this paper
• New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA

  2005cited by this paper
• Mapping of the Antibody-Binding Regions on the HN-Domain (Residues 449–859) of Botulinum Neurotoxin A with Antitoxin Antibodies from Four Host Species. Full Profile of the Continuous Antigenic Regions of the H-Chain of Botulinum Neurotoxin A

  2004cited by this paper
• Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.

  2000cited by this paper
• Complete regression of human B‐cell lymphoma xenografts in mice treated with recombinant anti‐CD22 immunotoxin RFB4(dsFv)‐PE38 at doses tolerated by cynomolgus monkeys

  1999cited by this paper
• Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855–1296 with antitoxin antibodies from three host species

  1996cited by this paper
• Administration of disulfide‐stabilized Fv‐immunotoxins B1(dsFv)‐PE38 and B3(dsFv)‐PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice

  1995cited by this paper
• Immunotoxin therapy of cancer.

  1993cited by this paper
• Immunotoxin therapy of cancer.

  1993cited by this paper
• Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family‐specific oligonucleotide probes

  1991influential reference
• By-passing immunization. Human antibodies from V-gene libraries displayed on phage.

  1991influential reference
• The interpretation of protein structures: estimation of static accessibility.

  1971cited by this paper

• Exploring Escherichia coli EGY Type II L-Asparaginase Variant of Unique Glutaminase Activity: Cloning, Expression, Biochemical Characterization, and Molecular Docking Analysis

  2025cites this paper
• Targeting glypican 3 by immunotoxins: the promise of immunotherapy in hepatocellular carcinoma

  2025cites this paper
• Research progress of drugs targeting GPC3 in cancer therapy.

  2025cites this paper
• In vitro anti-tumor activities of a novel recombinant immunotoxin targeting differentially overexpressed Leucine-rich repeat-containing G-protein-coupled receptor 5 in cervical cancer

  2025cites this paper
• Modular assembly and evaluation of a TROP2-targeting immunotoxin for cancer therapy.

  2025cites this paper
• Synthetic intrinsically disordered protein fusion tags that enhance protein solubility

  2024influential citation
• Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

  2024cites this paper
• Optimizing combination targeted immunotoxin therapy: Insights from HER2 and EpCAM expression profiles.

  2024cites this paper
• Compromising the immunogenicity of diphtheria toxin-based immunotoxins through epitope engineering: An in silico approach.

  2024cites this paper
• In silico design of a novel hybrid epitope-based antigen harboring highly exposed immunogenic peptides of BamA, OmpA, and Omp34 against Acinetobacter baumannii.

  2024cites this paper
• Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology

  2024cites this paper
• Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model

  2024cites this paper
• An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer

  2024cites this paper
• Deimmunization of flagellin adjuvant for clinical application.

  2023cites this paper
• Enhanced cytotoxicity of a Pseudomonas Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861

  2023influential citation
• Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH

  2023cites this paper
• Bringing enzymes to the proximity party

  2023cites this paper
• Synergistic Cytotoxicity of a Toxin Targeting the Epidermal Growth Factor Receptor and the Glycosylated Triterpenoid SO1861 in Prostate Cancer

  2023cites this paper
• Immunotoxins and Their Role in Prostate Cancer Treatment

  2023cites this paper
• Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Pseudomonas Exotoxin Catalytic Domain for Cancer Therapeutics

  2023cites this paper
• Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model

  2023cites this paper
• Accelerating therapeutic protein design with computational approaches toward the clinical stage

  2023cites this paper
• Artificial Scaffold Polypeptides As an Efficient Tool for the Targeted Delivery of Nanostructures In Vitro and In Vivo

  2022cites this paper
• Reduction of Pre-Existing Adaptive Immune Responses Against SaCas9 in Humans Using Epitope Mapping and Identification

  2022cites this paper
• Expression and Purification of Human Granzyme B Fusion Protein to Induce Targeted Apoptosis in PSMA Positive Prostate Cancer Cells.

  2022cites this paper
• The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury

  2022cites this paper
• Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells

  2022cites this paper
• Immunotoxin IHP25-BT with low immunogenicity and off-target toxicity inhibits the growth and metastasis of trastuzumab-resistant tumor cells.

  2021cites this paper
• Immunotherapy-based targeting of MSLN+ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis

  2021cites this paper
• Adapting protein sequences for optimized therapeutic efficacy.

  2021cites this paper
• Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin

  2021cites this paper
• The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis

  2021influential citation
• Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study

  2021cites this paper
• Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model

  2021cites this paper
• Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update

  2020cites this paper
• UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer

  2020cites this paper
• Engineered Anti‐GPC3 Immunotoxin, HN3‐ABD‐T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention

  2020cites this paper
• 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma

  2020cites this paper
• Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors

  2020cites this paper
• Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation

  2020cites this paper
• Anticancer Immunotoxins, Challenges, and Approaches.

  2020cites this paper
• Prediction of immunogenicity for humanized and full human therapeutic antibodies

  2020cites this paper
• The overexpressed antigens in triple negative breast cancer 1 and application in immunotherapy 2

  2020cites this paper
• GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets

  2020cites this paper
• Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer

  2020influential citation
• Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma

  2020cites this paper
• Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape

  2020cites this paper
• HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution

  2020cites this paper
• Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation

  2020cites this paper
• Application of therapeutic protein-based fusion toxins

  2019cites this paper
• HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model

  2019influential citation
• gain of diphtheria toxin binding of and mouse heparin-binding, epidermal growth factor-like growth factor precursors by reciprocal site-directed

  2019cites this paper
• Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin

  2019cites this paper
• A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells

  2019cites this paper
• Bioinformatics Predictions, Expression, Purification and Structural Analysis of the PE38KDEL-scfv Immunotoxin Against EPHA2 Receptor

  2019cites this paper
• Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.

  2019cites this paper
• Mesothelin-Targeted Agents in Mesothelioma

  2019cites this paper
• Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A

  2019cites this paper
• Immunotoxins: Targeted Toxin Delivery for Cancer Therapy

  2019cites this paper
• Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin

  2019cites this paper
• Novel immunotherapeutic approaches for hepatocellular carcinoma treatment

  2019cites this paper
• A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.

  2019cites this paper
• Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.

  2019cites this paper
• Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.

  2018cites this paper
• BIOLOGICAL PROPERTIES AND MEDICAL APPLICATION OF DIPHTHERIA TOXIN DERIVATIVES

  2018cites this paper
• Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin

  2018cites this paper
• In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer.

  2018cites this paper
• Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering

  2018cites this paper
• Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity

  2018cites this paper
• Antiviral Immunotoxin Against Bovine herpesvirus-1: Targeted Inhibition of Viral Replication and Apoptosis of Infected Cell

  2018cites this paper
• Immunogenicity assessment during the development of protein therapeutics

  2018cites this paper
• Construction and recombinant expression of Pseudomonas aeruginosa truncated exotoxin A in Escherichia coli.

  2018cites this paper
• Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.

  2018cites this paper
• Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins.

  2018cites this paper
• Human Granzyme B Based Targeted Cytolytic Fusion Proteins

  2018cites this paper
• DisruPPI: structure-based computational redesign algorithm for protein binding disruption

  2018cites this paper
• Immunity to CRISPR Cas9 and Cas12a therapeutics

  2018cites this paper
• Herstellung und Charakterisierung von CD13-spezifischen Antikörperderivaten für die diagnostische und therapeutische Anwendung bei hämatologischen und soliden Krebserkrankungen

  2017cites this paper
• Future Horizons and New Target Class Opportunities

  2017cites this paper
• Zielgerichtete Eliminierung autoreaktiver B-Lymphozyten mithilfe Antigen-basierter Fusionsproteine

  2017cites this paper
• Immunotoxin Therapy for Brain Tumors

  2017cites this paper
• Immunotoxin: A new tool for cancer therapy

  2017cites this paper
• Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges

  2017cites this paper
• Bifunctional Toxin DARP-LoPE Based on the Her2-Specific Innovative Module of a Non-Immunoglobulin Scaffold as a Promising Agent for Theranostics

  2017cites this paper
• Bioinformatic prediction and experimental validation of a PE38-based recombinant immunotoxin targeting the Fn14 receptor in cancer cells.

  2017cites this paper
• Immunotherapeutic Approaches to Mesothelioma

  2017cites this paper
• Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Deimmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins

  2017influential citation
• Clinical targeting recombinant immunotoxins for cancer therapy

  2017cites this paper
• CANCER CELL TARGETING: WHY ARE SO FEW ANTIBODY-DRUG CONJUGATES FDA APPROVED?

  2017cites this paper
• Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A

  2017cites this paper
• Introduction Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies

  2017cites this paper
• The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations

  2017cites this paper
• Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies

  2017cites this paper
• HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.

  2016cites this paper
• Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response

  2016cites this paper
• Countering immunotoxin immunogenicity

  2016influential citation
• Design and engineering of deimmunized biotherapeutics.

  2016cites this paper
• Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes

  2016cites this paper
• Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.

  2016cites this paper
• Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy

  2016cites this paper